Humana Ozempic Coverage for Weight Loss: What We Know

Last reviewed: June 15, 2026

Last updated: June 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

No insurer publishes a single nationwide answer on Ozempic for weight loss, and Humana is no exception — coverage runs through individual plan formularies that differ by product line, state and plan year. But there is a structural fact that predicts most of these outcomes before any formulary is consulted: the Ozempic prescribing information contains no weight-management indication. Its three indications are all in adults with type 2 diabetes. Plans overwhelmingly key coverage to the labeled indication and to diagnosis coding, so a weight-loss request routed to a diabetes-labeled product is fighting the paperwork, not the plan.

The Indication Is the Load-Bearing Fact

The Ozempic label lists three indications: improving glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes; reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

There is no BMI eligibility criterion anywhere in that document, because BMI is not part of any of its indications. Utilization management on this product is therefore built around diabetes diagnosis, prior therapy and glycemic markers — not around weight.

Where Weight-Management Coverage Actually Lives

The Wegovy label is the semaglutide document that covers weight reduction and long-term maintenance in adults and pediatric patients aged 12 and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity. It also carries a cardiovascular risk reduction indication in adults with established cardiovascular disease and either obesity or overweight.

That cardiovascular indication has been consequential for coverage discussions, because it gives plans a pathway that is not framed purely as weight management. Whether any particular plan uses it is a plan-level decision, and the only reliable source is that plan's own formulary and medical policy documents.

Why Medicare Plans Are a Separate Category

Humana has a large Medicare Advantage and Part D presence, and Part D operates under federal rules distinct from commercial benefit design. Historically, drugs used for weight loss occupied a different position under Part D than drugs used for a medically accepted indication, which is one reason coverage answers on this class have been inconsistent across product lines.

The practical consequence is that a friend's experience on a commercial plan tells you almost nothing about a Medicare Advantage plan, even from the same carrier. These are different contracts with different rules.

What a Prior Authorization Actually Asks For

Prior authorization criteria for this class typically request a diagnosis, documentation of prior therapy, relevant lab values and, where weight is the indication, anthropometric data and evidence of concurrent lifestyle intervention. Each element exists because the labeled indication requires it.

When a request is denied, the denial letter names the criterion that was not met. That letter is the most useful document in the process, because it converts a vague "not covered" into a specific gap that a prescriber can sometimes close on appeal with the right documentation.

The Questions That Get Real Answers

Calling a plan and asking whether Ozempic is covered produces an unhelpful answer. Asking whether a specific product is on the formulary, at which tier, for which indication, and what the prior authorization criteria are for that indication produces a usable one.

It is also worth asking whether the plan covers any product in the class for chronic weight management, since the answer may be a different brand entirely. Formulary preference in this category shifts between plan years more than in most therapeutic areas.

What Direct-Pay Changes and What It Does Not

Direct-pay clinical services remove the coverage question by removing the insurer. PlexusDx prescription GLP-1 protocols operate this way — clinical intake, prescriber decision, and dispensing from licensed 503A compounding pharmacies, with no membership and no insurance requirement.

What that does not change is regulatory category. Compounded semaglutide is not an FDA-approved finished product, and the FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. It is not a generic of Ozempic or Wegovy, neither of which has an approved generic. That distinction should be stated plainly by anyone offering it.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Does Humana cover Ozempic for weight loss?

Coverage is determined by the specific plan formulary and medical policy, which vary by product line, state and plan year, so there is no single answer. The structural obstacle is that the Ozempic prescribing information contains no weight-management indication; all three of its indications are in adults with type 2 diabetes. Plans generally key coverage to the labeled indication and diagnosis coding.

Is there a BMI requirement in the Ozempic label?

No. The Ozempic prescribing information contains no body mass index eligibility criterion, because none of its three indications concerns weight. Its indications cover glycemic control in adults with type 2 diabetes, cardiovascular risk reduction in those with established cardiovascular disease, and reduction of kidney and cardiovascular outcomes in those with chronic kidney disease.

Which semaglutide product has a weight-management indication?

Wegovy. Its labeling covers reducing excess body weight and maintaining weight reduction long term in adults and pediatric patients aged 12 and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity. Wegovy also carries a cardiovascular risk reduction indication and an accelerated-approval MASH indication.

What should I ask my plan to get a useful answer?

Ask whether the specific product is on the formulary, at which tier, for which indication, and what the prior authorization criteria are for that indication. Also ask whether any product in the class is covered for chronic weight management, since formulary preference in this category shifts between plan years. A general question about whether GLP-1 medications are covered is not actionable.

Why do Medicare Advantage answers differ from commercial plan answers?

They are different contracts operating under different rules. Part D benefit design follows federal requirements that historically treated drugs used for weight loss differently from drugs used for a medically accepted indication. As a result, an experience on a commercial plan tells you very little about a Medicare Advantage plan from the same carrier, and each must be checked separately.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.